Alkem Laboratories Ltd News Today

This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.

The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.

The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.

R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.

This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.

Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.

According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).